journal article
LitStream Collection
Home
Grossman, Nir; Okun, Michael S.; Boyden, Edward S.
doi: 10.1001/jamaneurol.2018.2760pmid: 30264149
This Viewpoint presents temporal interference stimulation, an optimized alternative to deep brain stimulation, transcranial magnetic stimulation, and transcranial electrical stimulation.
Zunhammer, Matthias; Bingel, Ulrike; Wager, Tor D.
doi: 10.1001/jamaneurol.2018.2017pmid: 30073258
Key PointsQuestionHow do placebo treatments affect pain processing in the brain? FindingsThis systematic meta-analysis of single-participant functional magnetic resonance imaging data of 603 healthy participants from 20 studies found that placebo treatments against experimental pain have moderate effects on pain reports, but very small effects on the neurologic pain signature, a cerebral measure of nociceptive pain. MeaningPlacebo analgesia seems to be predominantly mediated by networks different from those underlying the primary processing of noxious stimuli.
Howard, George; Schwamm, Lee H.; Donnelly, John P.; Howard, Virginia J.; Jasne, Adam; Smith, Eric E.; Rhodes, J. David; Kissela, Brett M.; Fonarow, Gregg C.; Kleindorfer, Dawn O.; Albright, Karen C.
Jiang, Rongcai; Zhao, Shiguang; Wang, Renzhi; Feng, Hua; Zhang, Jianmin; Li, Xingang; Mao, Ying; Yuan, Xianrui; Fei, Zhou; Zhao, Yuanli; Yu, Xinguang; Poon, Wai Sang; Zhu, Xide; Liu, Ning; Kang, Dezhi; Sun, Tao; Jiao, Baohua;
Wennberg, Alexandra M.; Tosakulwong, Nirubol; Lesnick, Timothy G.; Murray, Melissa E.; Whitwell, Jennifer L.; Liesinger, Amanda M.; Petrucelli, Leonard; Boeve, Bradley F.; Parisi, Joseph E.; Knopman, David S.; Petersen, Ronald C.; Dickson, Dennis W.; Josephs, Keith A.
López-Chiriboga, A. Sebastian; Majed, Masoud; Fryer, James; Dubey, Divyanshu; McKeon, Andrew; Flanagan, Eoin P.; Jitprapaikulsan, Jiraporn; Kothapalli, Naga; Tillema, Jan-Mendelt; Chen, John; Weinshenker, Brian; Wingerchuk, Dean; Sagen, Jessica; Gadoth, Avi;
Showing 1 to 10 of 26 Articles
Key PointsQuestionIs the quality of stroke care better at hospitals participating in Get With The Guidelines–Stroke? FindingsIn a longitudinal cohort study, 546 patients developed an ischemic stroke during follow-up. The odds of receiving 5 of 10 quality care metrics were higher among 207 patients admitted to a hospital participating in Get With The Guidelines–Stroke compared with 339 admitted to a nonparticipating hospital. MeaningThese data collected independently of the Get With The Guidelines–Stroke program document were associated with increased frequency of many aspects of care quality for hospitalized patients with ischemic stroke at hospitals participating in Get With The Guidelines–Stroke.
doi: 10.1001/jamaneurol.2018.2030pmid: 30073290
Key PointsQuestionCan atorvastatin treat chronic subdural hematoma? FindingsIn this randomized clinical trial, administering atorvastatin reduced chornic subdural hematomas by 29 mL vs 17 mL for placebo in 8 weeks. MeaningAtorvastatin is an effective conservative therapy of chronic subdural hematomas.
doi: 10.1001/jamaneurol.2018.3139pmid: 30422173
Key PointsQuestionIs there an association between apolipoprotein E (APOE) ε4 and transactive response DNA-binding protein 43 (TDP-43), and if so, is it mediated by β-amyloid and tau? FindingsIn this cross-sectional study of 738 older adults with an Alzheimer disease spectrum pathological diagnosis, the APOE ε4 allele was both directly (ie, independent of β-amyloid and tau) and indirectly (ie, mediated by β-amyloid and tau) associated with TDP-43. MeaningThe APOE ε4 allele appears to be a risk factor for TDP-43 in a model that accounts for age, β-amyloid, and tau, adding to the evidence that suggests that TDP-43 is a substantial factor in Alzheimer disease.
doi: 10.1001/jamaneurol.2018.1814pmid: 30014148
Key PointsQuestionWhat is the prognostic relevance of persistent seropositivity of antibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG1) in adults after acute disseminated encephalomyelitis (ADEM)? FindingsIn this cohort study of 51 patients with an initial diagnosis of ADEM, relapse occurred in 8 of 9 children and 7 of 8 adults with persistent MOG-IgG1 seropositivity. By contrast, relapse occurred in 6 of 17 children and 2 of 7 adults with MOG-IgG1 seronegativity as well as 0 of 4 children and 1 of 4 adults with transient MOG-IgG1 seropositivity. MeaningPersistent MOG-IgG1 positivity after recovery from ADEM in both pediatric and adult patients is useful as a longitudinal serological biomarker predicting risk for relapsing disease.